Cortical hyperexcitability and epileptogenesis: Understanding the mechanisms of epilepsy - Part 1

Journal of Clinical Neuroscience

Volumn 16, Issue 3, 2009, Pages 355-365

  Badawy, Radwa A B ^a,b   Harvey, Anthony S ^c   Macdonell, Richard A L ^a,b  

^a AUSTIN HEALTH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

Cellular excitability; Epilepsy; Epileptogenesis; Network excitability

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID B RECEPTOR; ION CHANNEL; VOLTAGE GATED CALCIUM CHANNEL; VOLTAGE GATED POTASSIUM CHANNEL;

ACTION POTENTIAL; BRAIN FUNCTION; BRAIN NERVE CELL; CHANNELOPATHY; ENVIRONMENTAL FACTOR; EPILEPSY; EPILEPTIC NERVE CELL; EPILEPTOGENESIS; GLIA CELL; HEREDITY; HUMAN; METABOLIC DISORDER; POSTSYNAPTIC POTENTIAL; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; SEIZURE;

ANIMALS; CEREBRAL CORTEX; EPILEPSY; HUMANS; ION CHANNEL GATING; ION CHANNELS; NEUROGLIA; NEURONS; SYNAPTIC TRANSMISSION;

EID: 59549102715     PISSN: 09675868     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jocn.2008.08.026     Document Type: Review

References (163)

1. McCormick D.A., and Contreras D. On the cellular and network bases of epileptic seizures. Annu Rev Physiol 63 (2001) 815-846
2. Clark S., and Wilson W.A. Mechanisms of epileptogenesis. Adv Neurol 79 (1999) 607-630
3. Binder D.K., and Steinhauser C. Functional changes in astroglial cells in epilepsy. Glia 54 (2006) 358-368
4. Dinocourt C., Petanjek Z., Freund T.F., et al. Loss of interneurons innervating pyramidal cell dendrites and axon initial segments in the CA1 region of the hippocampus following pilocarpine-induced seizures. J Comp Neurol 459 (2003) 407-425
5. Wittner L., Eross L., Czirjak S., et al. Surviving CA1 pyramidal cells receive intact perisomatic inhibitory input in the human epileptic hippocampus. Brain 128 (2005) 138-152
6. Jan L.Y., and Jan Y.N. Voltage-gated and inwardly rectifying potassium channels. J Physiol 505 (1997) 267-282
7. Miller C. An overview of the potassium channel family. Genome Biol 2000; 1:REVIEWS0004.
8. Ashcroft F.M. The Yin and Yang of the K(ATP) channel. J Physiol 528 (2000) 405
9. Catterall W.A. From ionic currents to molecular mechanisms: the structure and function of voltage-gated sodium channels. Neuron 26 (2000) 13-25
10. Schwartzkroin P.A. Basic mechanisms of epileptogenesis. In: Wylie E. (Ed). The Treatment of Epilepsy. First ed. (1993), Lea & Febiger, Philadelphia 83-98
11. 2+ channels. Annu Rev Cell Dev Biol 16 (2000) 521-555
12. 2+ -dependent afterhyperpolarization current in rat CA3 pyramidal cells in vitro. J Neurophysiol 80 (1998) 2268-2273
13. Elliott E.M., Malouf A.T., and Catterall W.A. Role of calcium channel subtypes in calcium transients in hippocampal CA3 neurons. J Neurosci 15 (1995) 6433-6444
14. Poncer J.C., McKinney R.A., Gahwiler B.H., et al. Either N- or P-type calcium channels mediate GABA release at distinct hippocampal inhibitory synapses. Neuron 18 (1997) 463-472
15. Jentsch T.J., and Gunther W. Chloride channels: an emerging molecular picture. Bioessays 19 (1997) 117-126
16. Grunder S., Thiemann A., Pusch M., et al. Regions involved in the opening of CIC-2 chloride channel by voltage and cell volume. Nature 360 (1992) 759-762
17. Jordt S.E., and Jentsch T.J. Molecular dissection of gating in the ClC-2 chloride channel. EMBO J 16 (1997) 1582-1592
18. Smith R.L., Clayton G.H., Wilcox C.L., et al. Differential expression of an inwardly rectifying chloride conductance in rat brain neurons: a potential mechanism for cell-specific modulation of postsynaptic inhibition. J Neurosci 15 (1995) 4057-4067
19. Staley K., Smith R., Schaack J., et al. Alteration of GABAA receptor function following gene transfer of the CLC-2 chloride channel. Neuron 17 (1996) 543-551
20. Itier V., and Bertrand D. Neuronal nicotinic receptors: from protein structure to function. FEBS Lett 504 (2001) 118-125
21. Chen Z.W., Chang C.S., Leil T.A., et al. GABAA receptor-associated protein regulates GABAA receptor cell-surface number in Xenopus laevis oocytes. Mol Pharmacol 68 (2005) 152-159
22. Wilson-Shaw D., Robinson M., Gambarana C., et al. A novel gamma subunit of the GABAA receptor identified using the polymerase chain reaction. FEBS Lett 284 (1991) 211-215
23. Bowery et al., 1980.
24. Misgeld U., Bijak M., and Jarolimek W. A physiological role for GABAB receptors and the effects of baclofen in the mammalian central nervous system. Prog Neurobiol 46 (1995) 423-462
25. Deisz R.A., Billard J.M., and Zieglgansberger W. Presynaptic and postsynaptic GABAB receptors of neocortical neurons of the rat in vitro: differences in pharmacology and ionic mechanisms. Synapse 25 (1997) 62-72
26. Johnston M.V. Developmental aspects of epileptogenesis. Epilepsia 37 Suppl 1 (1996) S2-S9
27. Raol Y.H., Lynch D.R., and Brooks-Kayal A.R. Role of excitatory amino acids in developmental epilepsies. Ment Retard Dev Disabil Res Rev 7 (2001) 254-260
28. Ptacek L.J., George Jr. A.L., Griggs R.C., et al. Identification of a mutation in the gene causing hyperkalemic periodic paralysis. Cell 67 (1991) 1021-1027
29. Ptacek L.J., and Fu Y.H. Channels and disease: past, present, and future. Arch Neurol 61 (2004) 1665-1668
30. Gardiner M. Genetics of idiopathic generalized epilepsies. Epilepsia 46 Suppl 9 (2005) 15-20
31. Zimprich F., Ronen G.M., Stogmann W., et al. Andreas Rett and benign familial neonatal convulsions revisited. Neurology 67 (2006) 864-866
32. Neyroud N., Tesson F., Denjoy I., et al. A novel mutation in the potassium channel gene KVLQT1 causes the Jervell and Lange-Nielsen cardioauditory syndrome. Nat Genet 15 (1997) 186-189
33. Cooper E.C., Aldape K.D., Abosch A., et al. Colocalization and coassembly of two human brain M-type potassium channel subunits that are mutated in epilepsy. Proc Natl Acad Sci USA 97 (2000) 4914-4919
34. Lerche H., Jurkat-Rott K., and Lehmann-Horn F. Ion channels and epilepsy. Am J Med Genet 106 (2001) 146-159
35. Schulte U., Thumfart J.O., Klocker N., et al. The epilepsy-linked Lgi1 protein assembles into presynaptic Kv1 channels and inhibits inactivation by Kvbeta1. Neuron 49 (2006) 697-706
36. Kalachikov S., Evgrafov O., Ross B., et al. Mutations in LGI1 cause autosomal-dominant partial epilepsy with auditory features. Nat Genet 30 (2002) 335-341
37. Cendes F., Kobayashi E., and Lopes-Cendes I. Familial temporal lobe epilepsy with auditory features. Epilepsia 46 Suppl 10 (2005) 59-60
38. Buckley C., and Vincent A. Autoimmune channelopathies. Nat Clin Prac 1 (2005) 22-33
39. Gultekin S.H., Rosenfeld M.R., Voltz R., et al. Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain 123 (2000) 1481-1494
40. Vincent A., Buckley C., Schott J.M., et al. Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain 127 (2004) 701-712
41. Thieben M.J., Lennon V.A., Boeve B.F., et al. Potentially reversible autoimmune limbic encephalitis with neuronal potassium channel antibody. Neurology 62 (2004) 1177-1182
42. Brewster A.L., Bernard J.A., Gall C.M., et al. Formation of heteromeric hyperpolarization-activated cyclic nucleotide-gated (HCN) channels in the hippocampus is regulated by developmental seizures. Neurobiol Dis 19 (2005) 200-207
43. Brewster A., Bender R.A., Chen Y., et al. Developmental febrile seizures modulate hippocampal gene expression of hyperpolarization-activated channels in an isoform- and cell-specific manner. J Neurosci 22 (2002) 4591-4599
44. Shah M.M., Anderson A.E., Leung V., et al. Seizure-induced plasticity of h channels in entorhinal cortical layer III pyramidal neurons. Neuron 44 (2004) 495-508
45. Bernard C., Anderson A., Becker A., et al. Acquired dendritic channelopathy in temporal lobe epilepsy. Science 305 (2004) 532-535
46. Castro P.A., Cooper E.C., Lowenstein D.H., et al. Hippocampal heterotopia lack functional Kv4.2 potassium channels in the methylazoxymethanol model of cortical malformations and epilepsy. J Neurosci 21 (2001) 6626-6634
47. Lucarini N., Verrotti A., Napolioni V., et al. Genetic polymorphisms and idiopathic generalized epilepsies. Pediatr Neurol 37 (2007) 157-164
48. Scheffer I.E., and Berkovic S.F. Generalized epilepsy with febrile seizures plus. A genetic disorder with heterogeneous clinical phenotypes. Brain 120 (1997) 479-490
49. Wallace R.H., Wang D.W., Singh R., et al. Febrile seizures and generalized epilepsy associated with a mutation in the Na+channel beta1 subunit gene SCN1B. Nat Genet 19 (1998) 366-370
50. Lossin C., Rhodes T.H., Desai R.R., et al. Epilepsy-associated dysfunction in the voltage-gated neuronal sodium channel SCN1A. J Neurosci 23 (2003) 11289-11295
51. Dravet C. Severe myoclonic epilepsy in infants and its related syndromes. Epilepsia 41 Suppl 9 (2000) 7
52. Lossin C., Wang D.W., Rhodes T.H., et al. Molecular basis of an inherited epilepsy. Neuron 34 (2002) 877-884
53. Heron S.E., Crossland K.M., Andermann E., et al. Sodium-channel defects in benign familial neonatal-infantile seizures. Lancet 360 (2002) 851-852
54. Berkovic S.F., Heron S.E., Giordano L., et al. Benign familial neonatal-infantile seizures: characterization of a new sodium channelopathy. Ann Neurol 55 (2004) 550-557
55. Shorvon S.D. Handbook of Epilepsy Treatment. First ed. (2000), Blackwell Science
56. Vreugdenhil M., and Wadman W.J. Modulation of sodium currents in rat CA1 neurons by carbamazepine and valproate after kindling epileptogenesis. Epilepsia 40 (1999) 1512-1522
57. Macdonald R.L., McLean M.J., and Skerritt J.H. Anticonvulsant drug mechanisms of action. Fed Proc 44 (1985) 2634-2639
58. Schachter S.C., Vazquez B., Fisher R.S., et al. Oxcarbazepine in a monotherapy trial for partial seizures - placebo-controlled studies in neurology: where do they stop?. Neurology 53 (1999) 2211-2212
59. Tecoma E.S. Oxcarbazepine. Epilepsia 40 Suppl 5 (1999) S37-S46
60. Cunnington M.C. The International Lamotrigine pregnancy registry update for the epilepsy foundation. Epilepsia 45 (2004) 1468
61. Matsuo F. Lamotrigine. Epilepsia 40 Suppl 5 (1999) S30-S36
62. Chadwick D.W., and Marson A.G. Zonisamide for drug-resistant partial epilepsy. Cochrane database of systematic reviews (Online) (2000) CD001416
63. Kyllerman M., and Ben-Menachem E. Zonisamide for progressive myoclonus epilepsy: long-term observations in seven patients. Epilepsy Res 29 (1998) 109-114
64. Leppik I.E. Zonisamide. Epilepsia 40 Suppl 5 (1999) S23-S29
65. Heron S.E., Khosravani H., Varela D., et al. Extended spectrum of idiopathic generalized epilepsies associated with CACNA1H functional variants. Ann Neurol 62 (2007) 560-568
66. Chen Y., Lu J., Pan H., et al. Association between genetic variation of CACNA1H and childhood absence epilepsy. Ann Neurol 54 (2003) 239-243
67. Fletcher C.F., Lutz C.M., O'Sullivan T.N., et al. Absence epilepsy in tottering mutant mice is associated with calcium channel defects. Cell 87 (1996) 607-617
68. 2+ channel defects in migraine, ataxia and epilepsy. Trends Pharmacol Sci 19 (1998) 121-127
69. Empson R.M., and Jefferys J.G. Ca(2+) entry through L-type Ca(2+) channels helps terminate epileptiform activity by activation of a Ca(2+) dependent afterhyperpolarisation in hippocampal CA3. Neuroscience 102 (2001) 297-306
70. Straub H., Kohling R., Frieler A., et al. Contribution of L-type calcium channels to epileptiform activity in hippocampal and neocortical slices of guinea-pigs. Neuroscience 95 (2000) 63-72
71. Ikegaya Y., Nishiyama N., and Matsuki N. L-type Ca(2+) channel blocker inhibits mossy fiber sprouting and cognitive deficits following pilocarpine seizures in immature mice. Neuroscience 98 (2000) 647-659
72. Hassan H., Grecksch G., Ruthrich H., et al. Effects of nicardipine, an antagonist of L-type voltage-dependent calcium channels, on kindling development, kindling-induced learning deficits and hippocampal potentiation phenomena. Neuropharmacology 38 (1999) 1841-1850
73. van Luijtelaar E.L., Ates N., and Coenen A.M. Role of L-type calcium channel modulation in nonconvulsive epilepsy in rats. Epilepsia 36 (1995) 86-92
74. Coulter D.A., Huguenard J.R., and Prince D.A. Specific petit mal anticonvulsants reduce calcium currents in thalamic neurons. Neurosci Lett 98 (1989) 74-78
75. Coulter D.A., Huguenard J.R., and Prince D.A. Characterization of ethosuximide reduction of low-threshold calcium current in thalamic neurons. Ann Neurol 25 (1989) 582-593
76. Haug K., Warnstedt M., Alekov A.K., et al. Mutations in CLCN2 encoding a voltage-gated chloride channel are associated with idiopathic generalized epilepsies. Nat Genet 33 (2003) 527-532
77. McLellan A., Phillips H.A., Rittey C., et al. Phenotypic comparison of two Scottish families with mutations in different genes causing autosomal dominant nocturnal frontal lobe epilepsy. Epilepsia 44 (2003) 613-617
78. Leniger T., Kananura C., Hufnagel A., et al. A new Chrna4 mutation with low penetrance in nocturnal frontal lobe epilepsy. Epilepsia 44 (2003) 981-985
79. Phillips H.A., Scheffer I.E., Crossland K.M., et al. Autosomal dominant nocturnal frontal-lobe epilepsy: genetic heterogeneity and evidence for a second locus at 15q24. Am J Hum Genet 63 (1998) 1108-1116
80. Scheffer I.E., Bhatia K.P., Lopes-Cendes I., et al. Autosomal dominant nocturnal frontal lobe epilepsy. A distinctive clinical disorder. Brain 118 (1995) 61-73
81. Scheffer I.E., Bhatia K.P., Lopes-Cendes I., et al. Autosomal dominant frontal epilepsy misdiagnosed as sleep disorder. Lancet 343 (1994) 515-517
82. Bertrand S., Weiland S., Berkovic S.F., et al. Properties of neuronal nicotinic acetylcholine receptor mutants from humans suffering from autosomal dominant nocturnal frontal lobe epilepsy. Br J Pharmacol 125 (1998) 751-760
83. Raggenbass M., and Bertrand D. Nicotinic receptors in circuit excitability and epilepsy. J Neurobiol 53 (2002) 580-589
84. Rodrigues-Pinguet N., Jia L., Li M., et al. Five ADNFLE mutations reduce the Ca2+ dependence of the mammalian alpha4beta2 acetylcholine response. J Physiol 550 (2003) 11-26
85. Cossette P., Liu L., Brisebois K., et al. Mutation of GABRA1 in an autosomal dominant form of juvenile myoclonic epilepsy. Nat Genet 31 (2002) 184-189
86. Baulac S., Huberfeld G., Gourfinkel-An I., et al. First genetic evidence of GABA(A) receptor dysfunction in epilepsy: a mutation in the gamma2-subunit gene. Nat Genet 28 (2001) 46-48
87. Harkin L.A., Bowser D.N., Dibbens L.M., et al. Truncation of the GABA(A)-receptor gamma2 subunit in a family with generalized epilepsy with febrile seizures plus. Am J Hum Genet 70 (2002) 530-536
88. Berkovic S.F., Mulley J.C., Scheffer I.E., et al. Human epilepsies: interaction of genetic and acquired factors. Trends Neurosci 29 (2006) 391-397
89. Karlsson G., Kolb C., Hausdorf A., et al. GABAB receptors in various in vitro and in vivo models of epilepsy: a study with the GABAB receptor blocker CGP 35348. Neuroscience 47 (1992) 63-68
90. Vergnes M., Boehrer A., Simler S., et al. Opposite effects of GABAB receptor antagonists on absences and convulsive seizures. Eur J Pharmacol 332 (1997) 245-255
91. Mangan P.S., and Lothman E.W. Profound disturbances of pre- and postsynaptic GABAB-receptor-mediated processes in region CA1 in a chronic model of temporal lobe epilepsy. J Neurophysiol 76 (1996) 1282-1296
92. Deisz R.A. The GABA(B) receptor antagonist CGP 55845A reduces presynaptic GABA(B) actions in neocortical neurons of the rat in vitro. Neuroscience 93 (1999) 1241-1249
93. Deisz R.A. Cellular mechanisms of pharmacoresistance in slices from epilepsy surgery. Novartis Foundation symposium 243 (2002) 186-199 discussion 199-206, 231-85
94. Kantrowitz J.T., Francis N.N., Salah A., et al. Synaptic depolarizing GABA Response in adults is excitatory and proconvulsive when GABAB receptors are blocked. J Neurophysiol 93 (2005) 2656-2667
95. Rogers S.W., Andrews P.I., Gahring L.C., et al. Autoantibodies to glutamate receptor GluR3 in Rasmussen's encephalitis. Science 265 (1994) 648-651
96. Bien C.G., Granata T., Antozzi C., et al. Pathogenesis, diagnosis and treatment of Rasmussen encephalitis: a European consensus statement. Brain 128 (2005) 454-471
97. McNamara J.O. Emerging insights into the genesis of epilepsy. Nature 399 Suppl (1999) A15-A22
98. Mantegazza R., Bernasconi P., Baggi F., et al. Antibodies against GluR3 peptides are not specific for Rasmussen's encephalitis but are also present in epilepsy patients with severe, early onset disease and intractable seizures. J Neuroimmunol 131 (2002) 179-185
99. Wiendl H., Bien C.G., Bernasconi P., et al. GluR3 antibodies: prevalence in focal epilepsy but no specificity for Rasmussen's encephalitis. Neurology 57 (2001) 1511-1514
100. D'Antuono M., Inaba Y., Biagini G., et al. Synaptic hyperexcitability of deep layer neocortical cells in a genetic model of absence seizures. Genes Brain Behav 5 (2006) 73-84
101. McNamara J.O. Cellular and molecular basis of epilepsy. J Neurosci 14 (1994) 3413-3425
102. Hwa G.G., and Avoli M. Excitatory synaptic transmission mediated by NMDA and non-NMDA receptors in the superficial/middle layers of the epileptogenic human neocortex maintained in vitro. Neurosci Lett 143 (1992) 83-86
103. Bender R.A., Soleymani S.V., Brewster A.L., et al. Enhanced expression of a specific hyperpolarization-activated cyclic nucleotide-gated cation channel (HCN) in surviving dentate gyrus granule cells of human and experimental epileptic hippocampus. J Neurosci 23 (2003) 6826-6836
104. Speckmann E.J., and Elger C.E. The neurophysiological basis of epileptic activity: a condensed overview. Epilepsy Res Suppl 2 (1991) 1-7
105. Ebersole J.S. Electrophysiologic methods of evaluating epilepsy. Semin Neurol 10 (1990) 339-348
106. Connors B.W., Gutnick M.J., and Prince D.A. Electrophysiological properties of neocortical neurons in vitro. J Neurophysiol 48 (1982) 1302-1320
107. Schwartzkroin P.A., and Haglund M.M. Spontaneous rhythmic synchronous activity in epileptic human and normal monkey temporal lobe. Epilepsia 27 (1986) 523-533
108. Connors B.W. Initiation of synchronized neuronal bursting in neocortex. Nature 310 (1984) 685-687
109. Jefferys J.G. Experimental neurobiology of epilepsies. Curr Opin Neurol 7 (1994) 113-122
110. Traub R.D., and Jefferys J.G. Are there unifying principles underlying the generation of epileptic afterdischarges in vitro?. Prog Brain Res 102 (1994) 383-394
111. Alger B.E., and Nicoll R.A. Epileptiform burst afterhyperolarization: calcium-dependent potassium potential in hippocampal CA1 pyramidal cells. Science 210 (1980) 1122-1124
112. McCormick D.A. GABA as an inhibitory neurotransmitter in human cerebral cortex. J Neurophysiol 62 (1989) 1018-1027
113. Scanziani M., Debanne D., Muller M., et al. Role of excitatory amino acid and GABAB receptors in the generation of epileptiform activity in disinhibited hippocampal slice cultures. Neuroscience 61 (1994) 823-832
114. Perez-Velazquez J.L., Valiante T.A., and Carlen P.L. Modulation of gap junctional mechanisms during calcium-free induced field burst activity: a possible role for electrotonic coupling in epileptogenesis. J Neurosci 14 (1994) 4308-4317
115. Sokoloff L. Relationships among local functional activity, energy metabolism, and blood flow in the central nervous system. Fed Proc 40 (1981) 2311-2316
116. Clarke J.F., Young P.W., Yonezawa K., et al. Inhibition of the translocation of GLUT1 and GLUT4 in 3T3-L1 cells by the phosphatidylinositol 3-kinase inhibitor, wortmannin. Biochem J 300 (1994) 631-635
117. Owen O.E., Morgan A.P., Kemp H.G., et al. Brain metabolism during fasting. J Clin Invest 46 (1967) 1589-1595
118. Stephenson J.B. Anoxic seizures: self-terminating syncopes. Epileptic Disord 3 (2001) 3-6
119. Mori T., and Nagai K. Carbon-monoxide poisoning presenting as an afebrile seizure. Pediatr Neurol 22 (2000) 330-331
120. Vannucci S.J., Seaman L.B., Brucklacher R.M., et al. Glucose transport in developing rat brain: glucose transporter proteins, rate constants and cerebral glucose utilization. Mol Cell Biochem 140 (1994) 177-184
121. Klepper J., and Voit T. Facilitated glucose transporter protein type 1 (GLUT1) deficiency syndrome: impaired glucose transport into brain-- a review. Eur J Pediatr 161 (2002) 295-304
122. Murphy P. Use of the ketogenic diet as a treatment for epilepsy refractory to drug treatment. Expert Rev Neurother 5 (2005) 769-775
123. Freeman J.M., Kossoff E.H., and Hartman A.L. The ketogenic diet: one decade later. Pediatrics 119 (2007) 535-543
124. Gilbert D.L., Pyzik P.L., and Freeman J.M. The ketogenic diet: seizure control correlates better with serum beta-hydroxybutyrate than with urine ketones. J Child Neurol 15 (2000) 787-790
125. Berkovic S.F., Andermann F., Carpenter S., et al. Progressive myoclonus epilepsies: specific causes and diagnosis. N Engl J Med 315 (1986) 296-305
126. Jaksch M., Klopstock T., Kurlemann G., et al. Progressive myoclonus epilepsy and mitochondrial myopathy associated with mutations in the tRNA(Ser(UCN)) gene. Ann Neurol 44 (1998) 635-640
127. Schuelke M., Bakker M., Stoltenburg G., et al. Epilepsia partialis continua associated with a homoplasmic mitochondrial tRNA(Ser(UCN)) mutation. Ann Neurol 44 (1998) 700-704
128. DiMauro S., Kulikova R., Tanji K., et al. Mitochondrial genes for generalized epilepsies. Adv Neurol 79 (1999) 411-419
129. Naviaux R.K., Nyhan W.L., Barshop B.A., et al. Mitochondrial DNA polymerase gamma deficiency and mtDNA depletion in a child with Alpers' syndrome. Ann Neurol 45 (1999) 54-58
130. Krajewski S., Krajewska M., Ellerby L.M., et al. Release of caspase-9 from mitochondria during neuronal apoptosis and cerebral ischemia. Proc Natl Acad Sci USA 96 (1999) 5752-5757
131. Kunz W.S. The role of mitochondria in epileptogenesis. Curr Opin Neurol 15 (2002) 179-184
132. Kohling R. Neuroscience. GABA becomes exciting. Science 298 (2002) 1350-1351
133. Meldrum B.S. The role of glutamate in epilepsy and other CNS disorders. Neurology 44 Suppl 8 (1994) S14-S23
134. Dingledine R., McBain C.J., and McNamara J.O. Excitatory amino acid receptors in epilepsy. Trends Pharmacol Sci 11 (1990) 334-338
135. De Deyn P.P., Marescau B., and MacDonald R.L. Epilepsy and the GABA-hypothesis a brief review and some examples. Acta Neurol Belg 90 (1990) 65-81
136. Wong R.K., and Watkins D.J. Cellular factors influencing GABA response in hippocampal pyramidal cells. J Neurophysiol 48 (1982) 938-951
137. Greenberg D.A., Cayanis E., Strug L., et al. Malic enzyme 2 may underlie susceptibility to adolescent-onset idiopathic generalized epilepsy. Am J Hum Genet 76 (2005) 139-146
138. Loscher W., and Schwartz-Porsche D. Low levels of gamma-aminobutyric acid in cerebrospinal fluid of dogs with epilepsy. J Neurochem 46 (1986) 1322-1325
139. Loscher W., and Schwark W.S. Evidence for impaired GABAergic activity in the substantia nigra of amygdaloid kindled rats. Brain Res 339 (1985) 146-150
140. Meldrum B.S. Update on the mechanism of action of antiepileptic drugs. Epilepsia 37 Suppl 6 (1996) S4-S11
141. Schmidt D. Clobazam for treatment of intractable epilepsy: a critical assessment. Epilepsia 35 Suppl 5 (1994) S92-S95
142. Remy C. Clobazam in the treatment of epilepsy: a review of the literature. Epilepsia 35 Suppl 5 (1994) S88-S91
143. Faught E. Pharmacokinetic considerations in prescribing antiepileptic drugs. Epilepsia 42 Suppl 4 (2001) 19-23
144. Aicardi J., Mumford J.P., Dumas C., et al. Vigabatrin as initial therapy for infantile spasms: a European retrospective survey. Sabril IS Investigator and Peer Review Groups. Epilepsia 37 (1996) 638-642
145. Lynex C.N., Carr I.M., Leek J.P., et al. Homozygosity for a missense mutation in the 67 kDa isoform of glutamate decarboxylase in a family with autosomal recessive spastic cerebral palsy: parallels with Stiff-Person Syndrome and other movement disorders. BMC Neurol 4 (2004) 20
146. Kash S.F., Johnson R.S., Tecott L.H., et al. Epilepsy in mice deficient in the 65-kDa isoform of glutamic acid decarboxylase. Proc Natl Acad Sci USA 94 (1997) 14060-14065
147. Vulliemoz S., Vanini G., Truffert A., et al. Epilepsy and cerebellar ataxia associated with anti-glutamic acid decarboxylase antibodies. J Neurol Neurosurg Psychiatry 78 (2007) 187-189
148. Dingledine R., Borges K., Bowie D., et al. The glutamate receptor ion channels. Pharmacol Rev 51 (1999) 7-61
149. Engelborghs S., D'Hooge R., and De Deyn P.P. Pathophysiology of epilepsy. Acta Neurol Belg 100 (2000) 201-213
150. van Gelder N.M., Janjua N.A., Metrakos K., et al. Plasma amino acids in 3/sec spike-wave epilepsy. Neurochem Res 5 (1980) 659-671
151. Rho J.M., and Sankar R. The pharmacologic basis of antiepileptic drug action. Epilepsia 40 (1999) 1471-1483
152. Bourgeois B.F. Felbamate in the treatment of partial-onset seizures. Epilepsia 35 Suppl 5 (1994) S58-S61
153. Privitera M.D. Topiramate: a new antiepileptic drug. Ann Pharmacother 31 (1997) 1164-1173
154. Gibbs III J.W., Sombati S., DeLorenzo R.J., et al. Cellular actions of topiramate: blockade of kainate-evoked inward currents in cultured hippocampal neurons. Epilepsia 41 Suppl 1 (2000) S10-S16
155. Shank R.P., Gardocki J.F., Vaught J.L., et al. Topiramate: preclinical evaluation of structurally novel anticonvulsant. Epilepsia 35 (1994) 450-460
156. Mori A., Hiramatsu M., Namba S., et al. Decreased dopamine level in the epileptic focus. Res Commun Chem Pathol Pharmacol 56 (1987) 157-164
157. Hara M., Sasa M., Kawabata A., et al. Decreased dopamine and increased norepinephrine levels in the spontaneously epileptic rat, a double mutant rat. Epilepsia 34 (1993) 433-440
158. Snead III O.C. Basic mechanisms of generalized absence seizures. Ann Neurol 37 (1995) 146-157
159. Noebels J.L. A single gene error of noradrenergic axon growth synchronizes central neurones. Nature 310 (1984) 409-411
160. Gerber K., Filakovszky J., Halasz P., et al. The 5-HT1A agonist 8-OH-DPAT increases the number of spike-wave discharges in a genetic rat model of absence epilepsy. Brain Res 807 (1998) 243-245
161. Meldrum B.S., Menini C., Stutzmann J.M., et al. Effects of opiate-like peptides, morphine, and naloxone in the photosensitive baboon, Papio papio. Brain Res 170 (1979) 333-348
162. Przewlocka B., Lason W., Machelska H., et al. Kappa opioid receptor agonists suppress absence seizures in WAG/Rij rats. Neurosci Lett 186 (1995) 131-134
163. Mayberg H.S., Sadzot B., Meltzer C.C., et al. Quantification of mu and non-mu opiate receptors in temporal lobe epilepsy using positron emission tomography. Ann Neurol 30 (1991) 3-11